Monopar Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Monopar Therapeutics Inc. (MNPR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $64.22 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-12
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-06-30 was $64.22, a 110.14% increase year-over-year.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $49.84, a 70.86% increase year-over-year.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-09-30 was $37.52, a 1189.35% increase year-over-year.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-06-30 was $30.56, a 1098.43% increase year-over-year.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $27.49, a 910.66% increase from fiscal 2024.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $2.72.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $2.13, a 52.24% decline from fiscal 2021.
- Monopar Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $4.46, a 50.61% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $64.22 10-Q · filed 2026-08-12 | $50.52 10-Q · filed 2026-08-12 | |||||
| 2026-03-31 | $49.84 10-Q · filed 2026-05-14 | ||||||
| 2025-12-31 | $27.49 10-K · filed 2026-03-27 | ||||||
| 2025-09-30 | $37.52 10-Q · filed 2025-11-13 | $29.98 10-Q · filed 2025-11-13 | |||||
| 2025-06-30 | $30.56 10-Q · filed 2026-08-12 | $29.23 10-Q · filed 2026-08-12 | |||||
| 2025-03-31 | $29.17 10-Q · filed 2026-05-14 | ||||||
| 2024-12-31 | $2.72 10-K · filed 2026-03-27 | ||||||
| 2024-09-30 | $2.91 10-Q · filed 2025-11-13 | $2.72 10-Q · filed 2025-11-13 | |||||
| 2024-06-30 | $2.55 10-Q · filed 2025-08-12 | $0.51 10-Q · filed 2024-08-09 | $2.40 10-Q · filed 2025-08-12 | $0.48 10-Q · filed 2024-08-09 | |||
| 2024-03-31 | $1.25 10-Q · filed 2025-05-13 | $0.25 10-Q · filed 2024-05-09 | |||||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-08 | $11.90 10-Q · filed 2024-11-08 | |||||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-09 | $2.38 10-Q · filed 2024-08-09 | |||||
| 2023-03-31 | $2.38 10-Q · filed 2024-05-09 | ||||||
| 2022-12-31 | $2.13 10-K · filed 2023-03-23 | ||||||
| 2022-09-30 | $1.60 10-Q · filed 2022-11-10 | $2.10 10-Q · filed 2022-11-10 | |||||
| 2022-06-30 | $2.00 10-Q · filed 2023-08-10 | $2.11 10-Q · filed 2023-08-10 | |||||
| 2022-03-31 | $2.11 10-Q · filed 2023-05-11 | ||||||
| 2021-12-31 | $4.46 10-K · filed 2023-03-23 | ||||||
| 2021-09-30 | $3.96 10-Q · filed 2022-11-10 | $4.48 10-Q · filed 2022-11-10 | |||||
| 2021-06-30 | $4.16 10-Q · filed 2022-08-11 | $4.64 10-Q · filed 2022-08-11 | |||||
| 2021-03-31 | $4.90 10-Q · filed 2022-05-12 | ||||||
| 2020-12-31 | $9.03 10-K · filed 2022-03-24 | ||||||
| 2020-09-30 | $3.87 10-Q · filed 2021-11-12 | $7.78 10-Q · filed 2021-11-12 | $9.05 10-Q · filed 2020-11-12 | ||||
| 2020-06-30 | $5.43 10-Q · filed 2021-08-12 | $9.22 10-Q · filed 2021-08-12 | $5.43 10-Q · filed 2020-08-06 | ||||
| 2020-03-31 | $9.34 10-Q · filed 2021-05-13 | $9.30 10-Q · filed 2020-05-07 | |||||
| 2019-06-30 | $9.22 10-Q · filed 2020-08-06 | $9.22 10-Q · filed 2020-08-06 | $3.30 10-Q · filed 2019-08-08 | ||||
| 2018-03-31 | $3.20 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |